3002.13.00.90/Unmixed Monoclonal Antibody Bevacizumab/Canada

Unmixed Monoclonal Antibody Bevacizumab from Canada

Bevacizumab is a recombinant humanized monoclonal antibody that inhibits vascular endothelial growth factor (VEGF) for therapeutic use in cancer treatment. It falls under HTS 3002.13.0090 as an unmixed immunological product not put up in measured doses or retail packaging, directly involved in regulating immunological processes. This classification applies to bulk biotech-derived antibodies for further pharmaceutical processing.

Duty Rate — Canada → United States

0%

Rate breakdown

9903.03.030%Articles the product of any country, as provided for in subdivision (aa)(ii) of U.S. note 2 to this subchapter
Calculate with your customs valueVerify classification with AI

Import Tips

• Verify FDA biologics license and provide certificates of analysis confirming purity and biotech origin to avoid misclassification as Chapter 29 chemicals

• Ensure cold chain documentation (2-8°C) during import to maintain product integrity, as deviations can lead to customs holds

• Declare exact concentration and absence of excipients to confirm 'unmixed' status; common pitfall is classifying diluted solutions under 3002.14

Unmixed Monoclonal Antibody Bevacizumab from Canada — Import Duty Rate | HTS 3002.13.00.90